查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1344454

化療引起的貧血市場：按等級、按治療、按最終用戶：2023-2032 年全球機會分析和產業預測

Chemotherapy Induced Anemia Market By Grade, By Treatment, By End User : Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 249 Pages | 商品交期: 2-3個工作天內

價格

2022 年化療引起的貧血市場價值為 27 億美元，預計 2023 年至 2032 年複合年增長率為 6.3%，到 2032 年將達到 50 億美元。Masu。

化療引起的貧血 (CIA) 是一種特殊類型的貧血，是癌症化療的副作用。 化療藥物會破壞負責產生紅血球的骨髓的正常功能。 結果，體內循環的紅血球數量減少，導致貧血。 CIA 會引起多種症狀，包括疲勞、虛弱、氣短、頭暈和皮膚蒼白。 這些症狀會對接受化療的癌症患者的生活品質和整體健康產生重大影響。 CIA 的治療包括輸血、紅血球生成刺激劑 (ESA)、鐵和其他鐵補充劑。

化療引起的貧血市場-IMG1

癌症盛行率不斷上升、對標靶治療的需求不斷增加以及人口迅速老化，推動了化療引起的貧血市場的成長。 癌症盛行率的增加和化療的伴隨使用預計將在未來繼續推動化療引起的貧血市場的成長。 例如，2022 年 2 月，世界衛生組織 (WHO) 估計全球每年約有 40 萬名兒童罹患癌症。 此外，美國國家生物技術資訊中心 (NCBI) 在 2022 年 4 月進行的一項研究估計，乳癌患者貧血的發生率約為 41.1%。 因此，癌症盛行率的上升將推動市場成長。 此外，老年人更有可能患癌症和貧血，這進一步推動了對治療化療引起的貧血的藥物的需求。

對化療引起的貧血的需求不斷增加是推動化療引起的貧血市場成長的主要因素。 這是由於貧血的發生率增加、人口老化以及有效治療的可用性。 高齡化社會更容易患癌症，導致 CIA 治療的需求增加。 此外，針對 CIA 的新的、更有效的治療方法的開發，例如紅血球生成刺激劑 (ESA) 和鐵補充劑，擴大了化療期間治療貧血的選擇。 補鐵是治療化療引起的貧血的有效方法，因為它比其他治療方法副作用更少。

例如，世界衛生組織 (WHO) 於 2022 年 10 月估計，到 2050 年，全球 60 歲及以上人口將增加一倍，達到 21 億。 此外，根據國家生物技術資訊中心 (NCBI) 的數據，老年人更有可能因癌症治療而出現貧血。 此外，患者和醫療保健專業人員對化療引起的貧血的認識不斷提高，尋求 CIA 治療的患者數量也在增加。 此外，政府加強癌症治療和化療引起的貧血（CIA）治療的措施也進一步推動了市場成長。 例如，2020 年 5 月，聯邦政府宣布將在五年內向加拿大抗癌夥伴關係投資 1.5 億加元，該夥伴關係的重點是改善癌症治療的可及性並為患者提供支持。 因此，政府不斷採取的措施進一步推動了市場成長。

然而，化療治療貧血的高成本以及與 ESA 相關的副作用限制了這些治療方法的採用，並對市場成長產生了負面影響。 例如，輸血每品脫血液的費用在 200 至 300 美元之間。 因此，輸血和其他藥物的高成本對市場成長有負面影響。 另一方面，探索副作用較小的治療化療引起的貧血的新療法以及增加先進治療方法的研發活動，為預測期內化療引起的貧血市場的增長提供了巨大的機會。預計會帶來。

目錄

第一章簡介

第 2 章執行摘要

第三章市場概述

  • 市場定義和範圍
  • 主要發現
    • 影響因素
    • 主要投資機會
  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭強度
  • 市場動態
    • 促進因素
      • 癌症發生率增加
      • 透過化療治療貧血的需求不斷增加
    • 抑制因素
      • 化療治療貧血的費用很高
      • 與紅血球生成刺激因子製劑相關的副作用
    • 機會
      • 開發新療法
  • 新冠肺炎 (COVID-19) 市場影響分析

第 4 章化療引起的貧血市場：依等級

  • 摘要
  • 1年級
  • 二年級
  • 三年級和四年級

第五章化療引起的貧血市場：依治療方式

  • 摘要
  • 輸血
  • 紅血球生成刺激因子製劑
  • 鐵和其他用品

第 6 章化療引起的貧血市場：依最終使用者劃分

  • 摘要
  • 醫院
  • 癌症中心
  • 其他

第七章化療引起的貧血市場：依地區

  • 摘要
  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 澳大利亞
    • 印度
    • 韓國
    • 其他亞太地區
  • 拉丁美洲/中東/非洲
    • 巴西
    • 沙烏地阿拉伯
    • 南非
    • 其他領域

第八章競爭態勢

  • 簡介
  • 關鍵成功策略
  • 10家主要公司的產品圖譜
  • 競爭對手儀表板
  • 競爭熱圖
  • 2022 年主要公司的定位

第九章公司簡介

  • Pfizer Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Johnson & Johnson
  • Amgen Inc.
  • Novartis AG
  • 3SBio Group
  • FibroGen, Inc.
  • Astellas Pharma Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
Product Code: A10539

According to a new report published by Allied Market Research, titled, "Chemotherapy Induced Anemia Market," The chemotherapy induced anemia market was valued at $2.7 billion in 2022, and is estimated to reach $5 billion by 2032, growing at a CAGR of 6.3% from 2023 to 2032. Chemotherapy-induced anemia (CIA) is a specific type of anemia that occurs as a side effect of chemotherapy treatment for cancer. Chemotherapy drugs can disrupt the normal functioning of the bone marrow, which is responsible for producing red blood cells. As a result, there is a decrease in the number of red blood cells circulating in the body, leading to anemia. CIA can cause various symptoms such as fatigue, weakness, shortness of breath, dizziness, and pale skin. These symptoms can significantly impact the quality of life and overall well-being of cancer patients undergoing chemotherapy. The treatment of CIA includes blood transfusion, erythropoiesis-stimulating agents (ESAs), and iron & other Iron supplementation.

Chemotherapy Induced Anemia Market - IMG1

The chemotherapy induced anemia market growth is driven by increase in prevalence of cancer, rise in demand for targeted therapies, and surge in aging population. The increasing prevalence of cancer and the associated use of chemotherapy is expected to continue to drive the growth of the chemotherapy-induced anemia market. For instance, in February 2022, the World Health Organization (WHO) estimated that approximately 400,000 children develop cancer every year across the globe. In addition, a study conducted by the National Center for Biotechnology Information (NCBI) in April 2022 estimated the occurrence rate of anemia was about 41.1% in patients suffering from breast cancer. Therefore, the rise in prevalence of cancer drives the growth of the market. In addition, older people are more likely to develop cancer and anemia, which further fuels the demand for drugs to treat chemotherapy induced anemia.

Rise in demand for chemotherapy induced anemia is the key factor driving the growth of chemotherapy induced anemia market. This is attributed to an increase in appearance of anemia, rise in ageing population, and availability of effective treatment. The aging population is more susceptible to developing cancer, leading to a higher demand for CIA treatment. In addition, development of new and more effective treatments for CIA, including erythropoiesis-stimulating agents (ESAs) and iron supplementation, has expanded the options available for managing anemia during chemotherapy. Iron supplement is an effective treatment for chemotherapy induced anemia as it has low side-effects as compared with other treatment options.

For instance, in October 2022, the World Health Organization (WHO) estimated that the global population aged 60 years and over is expected to double by 2050 to reach 2.1 billion. Moreover, according to the National Center for Biotechnology Information (NCBI), older adults are more likely to experience anemia as a result of cancer treatment. Furthermore, increase in awareness about chemotherapy induced anemia among patients and healthcare professionals has led to an increase in the number of patients seeking treatment for CIA. In addition, rise in government initiatives to improve cancer care and the treatment of chemotherapy-induced anemia (CIA) further propels the market growth. For instance, the federal government announced in May 2020 that it would be investing $150 million over five years in the Canadian Partnership against Cancer, with a focus on improving access to cancer care and support for patients. Thus, a rise in government initiatives further boosts the market growth.

However, the high cost of chemotherapy induced anemia therapies and side effects associated with the ESAs limit the adoption of these treatments, which negatively impacts the market growth. For instance, the cost of blood transfusion ranges from $200 to $300 per pint of blood. Thus, the high cost of blood transfusion and other drugs negatively impact market growth. On the other hand, development of novel therapies for the treatment of chemotherapy induced anemia with lower side effects and increase in R&D activities for developing advanced therapies are expected to create immense opportunities for the growth of chemotherapy induced anemia market during the forecast period. The chemotherapy induced anemia market is segmented on the basis of grade, treatment, end user, and region. On the basis of grade, the market is classified into grade 1, grade 2, and grade 3&4. As per treatment, the market is segmented into blood transfusion, erythropoietin-stimulating agents, and iron & other supplements.

On the basis of end user, the market is segmented into hospitals, cancer centers, and others. The other segment includes cancer research centers, cancer rehabilitation centers, and home use. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the global chemotherapy induced anemia market are Pfizer Inc., Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche Ltd., Johnson & Johnson, Amgen Inc., Novartis AG, 3SBio Group, Bristol-Myers Squibb Company, FibroGen, Inc., and Astella Pharma

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the chemotherapy induced anemia market analysis from 2022 to 2032 to identify the prevailing chemotherapy induced anemia market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the chemotherapy induced anemia market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global chemotherapy induced anemia market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Grade

  • Grade 1
  • Grade 2
  • Grade 3 and 4

By Treatment

  • Blood transfusion
  • Erythropoiesis stimulating agents
    • Type
    • Long Acting Erythropoietin stimulating agents
    • Short Acting Erythropoietin stimulating agents
  • Iron and others supplementation

By End User

  • Hospitals
  • Cancer center
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Dr. Reddy's Laboratories Ltd.
    • 3SBio Group
    • Johnson & Johnson
    • FibroGen, Inc.
    • Novartis AG
    • Pfizer Inc.
    • Amgen Inc.
    • Astellas Pharma Inc.
    • F. Hoffmann-La Roche Ltd.
    • Bristol-Myers Squibb Company

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Bargaining power of suppliers
    • 3.3.2. Bargaining power of buyers
    • 3.3.3. Threat of substitutes
    • 3.3.4. Threat of new entrants
    • 3.3.5. Intensity of rivalry
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Increase in prevalence of cancer
      • 3.4.1.2. Increase in demand for chemotherapy induced anemia treatment
    • 3.4.2. Restraints
      • 3.4.2.1. High cost of chemotherapy induced anemia treatments
      • 3.4.2.2. Side effects associated with erythropoiesis stimulating agents
    • 3.4.3. Opportunities
      • 3.4.3.1. Development of novel therapies
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: CHEMOTHERAPY INDUCED ANEMIA MARKET, BY GRADE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Grade 1
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Grade 2
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Grade 3 and 4
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country

CHAPTER 5: CHEMOTHERAPY INDUCED ANEMIA MARKET, BY TREATMENT

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Blood transfusion
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Erythropoiesis stimulating agents
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
    • 5.3.4. Erythropoiesis stimulating agents Chemotherapy Induced Anemia Market by Type
  • 5.4. Iron and others supplementation
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country

CHAPTER 6: CHEMOTHERAPY INDUCED ANEMIA MARKET, BY END USER

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospitals
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Cancer center
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Others
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: CHEMOTHERAPY INDUCED ANEMIA MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key trends and opportunities
    • 7.2.2. Market size and forecast, by Grade
    • 7.2.3. Market size and forecast, by Treatment
    • 7.2.4. Market size and forecast, by End User
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Key market trends, growth factors and opportunities
      • 7.2.5.1.2. Market size and forecast, by Grade
      • 7.2.5.1.3. Market size and forecast, by Treatment
      • 7.2.5.1.4. Market size and forecast, by End User
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Key market trends, growth factors and opportunities
      • 7.2.5.2.2. Market size and forecast, by Grade
      • 7.2.5.2.3. Market size and forecast, by Treatment
      • 7.2.5.2.4. Market size and forecast, by End User
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Key market trends, growth factors and opportunities
      • 7.2.5.3.2. Market size and forecast, by Grade
      • 7.2.5.3.3. Market size and forecast, by Treatment
      • 7.2.5.3.4. Market size and forecast, by End User
  • 7.3. Europe
    • 7.3.1. Key trends and opportunities
    • 7.3.2. Market size and forecast, by Grade
    • 7.3.3. Market size and forecast, by Treatment
    • 7.3.4. Market size and forecast, by End User
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Key market trends, growth factors and opportunities
      • 7.3.5.1.2. Market size and forecast, by Grade
      • 7.3.5.1.3. Market size and forecast, by Treatment
      • 7.3.5.1.4. Market size and forecast, by End User
      • 7.3.5.2. France
      • 7.3.5.2.1. Key market trends, growth factors and opportunities
      • 7.3.5.2.2. Market size and forecast, by Grade
      • 7.3.5.2.3. Market size and forecast, by Treatment
      • 7.3.5.2.4. Market size and forecast, by End User
      • 7.3.5.3. UK
      • 7.3.5.3.1. Key market trends, growth factors and opportunities
      • 7.3.5.3.2. Market size and forecast, by Grade
      • 7.3.5.3.3. Market size and forecast, by Treatment
      • 7.3.5.3.4. Market size and forecast, by End User
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Key market trends, growth factors and opportunities
      • 7.3.5.4.2. Market size and forecast, by Grade
      • 7.3.5.4.3. Market size and forecast, by Treatment
      • 7.3.5.4.4. Market size and forecast, by End User
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Key market trends, growth factors and opportunities
      • 7.3.5.5.2. Market size and forecast, by Grade
      • 7.3.5.5.3. Market size and forecast, by Treatment
      • 7.3.5.5.4. Market size and forecast, by End User
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Key market trends, growth factors and opportunities
      • 7.3.5.6.2. Market size and forecast, by Grade
      • 7.3.5.6.3. Market size and forecast, by Treatment
      • 7.3.5.6.4. Market size and forecast, by End User
  • 7.4. Asia-Pacific
    • 7.4.1. Key trends and opportunities
    • 7.4.2. Market size and forecast, by Grade
    • 7.4.3. Market size and forecast, by Treatment
    • 7.4.4. Market size and forecast, by End User
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Key market trends, growth factors and opportunities
      • 7.4.5.1.2. Market size and forecast, by Grade
      • 7.4.5.1.3. Market size and forecast, by Treatment
      • 7.4.5.1.4. Market size and forecast, by End User
      • 7.4.5.2. China
      • 7.4.5.2.1. Key market trends, growth factors and opportunities
      • 7.4.5.2.2. Market size and forecast, by Grade
      • 7.4.5.2.3. Market size and forecast, by Treatment
      • 7.4.5.2.4. Market size and forecast, by End User
      • 7.4.5.3. Australia
      • 7.4.5.3.1. Key market trends, growth factors and opportunities
      • 7.4.5.3.2. Market size and forecast, by Grade
      • 7.4.5.3.3. Market size and forecast, by Treatment
      • 7.4.5.3.4. Market size and forecast, by End User
      • 7.4.5.4. India
      • 7.4.5.4.1. Key market trends, growth factors and opportunities
      • 7.4.5.4.2. Market size and forecast, by Grade
      • 7.4.5.4.3. Market size and forecast, by Treatment
      • 7.4.5.4.4. Market size and forecast, by End User
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Key market trends, growth factors and opportunities
      • 7.4.5.5.2. Market size and forecast, by Grade
      • 7.4.5.5.3. Market size and forecast, by Treatment
      • 7.4.5.5.4. Market size and forecast, by End User
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Key market trends, growth factors and opportunities
      • 7.4.5.6.2. Market size and forecast, by Grade
      • 7.4.5.6.3. Market size and forecast, by Treatment
      • 7.4.5.6.4. Market size and forecast, by End User
  • 7.5. LAMEA
    • 7.5.1. Key trends and opportunities
    • 7.5.2. Market size and forecast, by Grade
    • 7.5.3. Market size and forecast, by Treatment
    • 7.5.4. Market size and forecast, by End User
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Key market trends, growth factors and opportunities
      • 7.5.5.1.2. Market size and forecast, by Grade
      • 7.5.5.1.3. Market size and forecast, by Treatment
      • 7.5.5.1.4. Market size and forecast, by End User
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Key market trends, growth factors and opportunities
      • 7.5.5.2.2. Market size and forecast, by Grade
      • 7.5.5.2.3. Market size and forecast, by Treatment
      • 7.5.5.2.4. Market size and forecast, by End User
      • 7.5.5.3. South Africa
      • 7.5.5.3.1. Key market trends, growth factors and opportunities
      • 7.5.5.3.2. Market size and forecast, by Grade
      • 7.5.5.3.3. Market size and forecast, by Treatment
      • 7.5.5.3.4. Market size and forecast, by End User
      • 7.5.5.4. Rest of LAMEA
      • 7.5.5.4.1. Key market trends, growth factors and opportunities
      • 7.5.5.4.2. Market size and forecast, by Grade
      • 7.5.5.4.3. Market size and forecast, by Treatment
      • 7.5.5.4.4. Market size and forecast, by End User

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

  • 9.1. Pfizer Inc.
    • 9.1.1. Company overview
    • 9.1.2. Key Executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
  • 9.2. Dr. Reddy's Laboratories Ltd.
    • 9.2.1. Company overview
    • 9.2.2. Key Executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
  • 9.3. Johnson & Johnson
    • 9.3.1. Company overview
    • 9.3.2. Key Executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
  • 9.4. Amgen Inc.
    • 9.4.1. Company overview
    • 9.4.2. Key Executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
  • 9.5. Novartis AG
    • 9.5.1. Company overview
    • 9.5.2. Key Executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
  • 9.6. 3SBio Group
    • 9.6.1. Company overview
    • 9.6.2. Key Executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
  • 9.7. FibroGen, Inc.
    • 9.7.1. Company overview
    • 9.7.2. Key Executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
  • 9.8. Astellas Pharma Inc.
    • 9.8.1. Company overview
    • 9.8.2. Key Executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
  • 9.9. Bristol-Myers Squibb Company
    • 9.9.1. Company overview
    • 9.9.2. Key Executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
  • 9.10. F. Hoffmann-La Roche Ltd.
    • 9.10.1. Company overview
    • 9.10.2. Key Executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance

LIST OF TABLES

  • TABLE 01. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET, BY GRADE, 2022-2032 ($MILLION)
  • TABLE 02. CHEMOTHERAPY INDUCED ANEMIA MARKET FOR GRADE 1, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. CHEMOTHERAPY INDUCED ANEMIA MARKET FOR GRADE 2, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. CHEMOTHERAPY INDUCED ANEMIA MARKET FOR GRADE 3 AND 4, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 06. CHEMOTHERAPY INDUCED ANEMIA MARKET FOR BLOOD TRANSFUSION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. CHEMOTHERAPY INDUCED ANEMIA MARKET FOR ERYTHROPOIESIS STIMULATING AGENTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 08. GLOBAL ERYTHROPOIESIS STIMULATING AGENTS CHEMOTHERAPY INDUCED ANEMIA MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 09. CHEMOTHERAPY INDUCED ANEMIA MARKET FOR IRON AND OTHERS SUPPLEMENTATION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 11. CHEMOTHERAPY INDUCED ANEMIA MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. CHEMOTHERAPY INDUCED ANEMIA MARKET FOR CANCER CENTER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. CHEMOTHERAPY INDUCED ANEMIA MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. CHEMOTHERAPY INDUCED ANEMIA MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. NORTH AMERICA CHEMOTHERAPY INDUCED ANEMIA MARKET, BY GRADE, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA CHEMOTHERAPY INDUCED ANEMIA MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 17. NORTH AMERICA CHEMOTHERAPY INDUCED ANEMIA MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 18. NORTH AMERICA CHEMOTHERAPY INDUCED ANEMIA MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 19. U.S. CHEMOTHERAPY INDUCED ANEMIA MARKET, BY GRADE, 2022-2032 ($MILLION)
  • TABLE 20. U.S. CHEMOTHERAPY INDUCED ANEMIA MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 21. U.S. CHEMOTHERAPY INDUCED ANEMIA MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 22. CANADA CHEMOTHERAPY INDUCED ANEMIA MARKET, BY GRADE, 2022-2032 ($MILLION)
  • TABLE 23. CANADA CHEMOTHERAPY INDUCED ANEMIA MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 24. CANADA CHEMOTHERAPY INDUCED ANEMIA MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 25. MEXICO CHEMOTHERAPY INDUCED ANEMIA MARKET, BY GRADE, 2022-2032 ($MILLION)
  • TABLE 26. MEXICO CHEMOTHERAPY INDUCED ANEMIA MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 27. MEXICO CHEMOTHERAPY INDUCED ANEMIA MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 28. EUROPE CHEMOTHERAPY INDUCED ANEMIA MARKET, BY GRADE, 2022-2032 ($MILLION)
  • TABLE 29. EUROPE CHEMOTHERAPY INDUCED ANEMIA MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 30. EUROPE CHEMOTHERAPY INDUCED ANEMIA MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 31. EUROPE CHEMOTHERAPY INDUCED ANEMIA MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 32. GERMANY CHEMOTHERAPY INDUCED ANEMIA MARKET, BY GRADE, 2022-2032 ($MILLION)
  • TABLE 33. GERMANY CHEMOTHERAPY INDUCED ANEMIA MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 34. GERMANY CHEMOTHERAPY INDUCED ANEMIA MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 35. FRANCE CHEMOTHERAPY INDUCED ANEMIA MARKET, BY GRADE, 2022-2032 ($MILLION)
  • TABLE 36. FRANCE CHEMOTHERAPY INDUCED ANEMIA MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 37. FRANCE CHEMOTHERAPY INDUCED ANEMIA MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 38. UK CHEMOTHERAPY INDUCED ANEMIA MARKET, BY GRADE, 2022-2032 ($MILLION)
  • TABLE 39. UK CHEMOTHERAPY INDUCED ANEMIA MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 40. UK CHEMOTHERAPY INDUCED ANEMIA MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 41. ITALY CHEMOTHERAPY INDUCED ANEMIA MARKET, BY GRADE, 2022-2032 ($MILLION)
  • TABLE 42. ITALY CHEMOTHERAPY INDUCED ANEMIA MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 43. ITALY CHEMOTHERAPY INDUCED ANEMIA MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 44. SPAIN CHEMOTHERAPY INDUCED ANEMIA MARKET, BY GRADE, 2022-2032 ($MILLION)
  • TABLE 45. SPAIN CHEMOTHERAPY INDUCED ANEMIA MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 46. SPAIN CHEMOTHERAPY INDUCED ANEMIA MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 47. REST OF EUROPE CHEMOTHERAPY INDUCED ANEMIA MARKET, BY GRADE, 2022-2032 ($MILLION)
  • TABLE 48. REST OF EUROPE CHEMOTHERAPY INDUCED ANEMIA MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 49. REST OF EUROPE CHEMOTHERAPY INDUCED ANEMIA MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 50. ASIA-PACIFIC CHEMOTHERAPY INDUCED ANEMIA MARKET, BY GRADE, 2022-2032 ($MILLION)
  • TABLE 51. ASIA-PACIFIC CHEMOTHERAPY INDUCED ANEMIA MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 52. ASIA-PACIFIC CHEMOTHERAPY INDUCED ANEMIA MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 53. ASIA-PACIFIC CHEMOTHERAPY INDUCED ANEMIA MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 54. JAPAN CHEMOTHERAPY INDUCED ANEMIA MARKET, BY GRADE, 2022-2032 ($MILLION)
  • TABLE 55. JAPAN CHEMOTHERAPY INDUCED ANEMIA MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 56. JAPAN CHEMOTHERAPY INDUCED ANEMIA MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 57. CHINA CHEMOTHERAPY INDUCED ANEMIA MARKET, BY GRADE, 2022-2032 ($MILLION)
  • TABLE 58. CHINA CHEMOTHERAPY INDUCED ANEMIA MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 59. CHINA CHEMOTHERAPY INDUCED ANEMIA MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 60. AUSTRALIA CHEMOTHERAPY INDUCED ANEMIA MARKET, BY GRADE, 2022-2032 ($MILLION)
  • TABLE 61. AUSTRALIA CHEMOTHERAPY INDUCED ANEMIA MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 62. AUSTRALIA CHEMOTHERAPY INDUCED ANEMIA MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 63. INDIA CHEMOTHERAPY INDUCED ANEMIA MARKET, BY GRADE, 2022-2032 ($MILLION)
  • TABLE 64. INDIA CHEMOTHERAPY INDUCED ANEMIA MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 65. INDIA CHEMOTHERAPY INDUCED ANEMIA MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 66. SOUTH KOREA CHEMOTHERAPY INDUCED ANEMIA MARKET, BY GRADE, 2022-2032 ($MILLION)
  • TABLE 67. SOUTH KOREA CHEMOTHERAPY INDUCED ANEMIA MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 68. SOUTH KOREA CHEMOTHERAPY INDUCED ANEMIA MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 69. REST OF ASIA-PACIFIC CHEMOTHERAPY INDUCED ANEMIA MARKET, BY GRADE, 2022-2032 ($MILLION)
  • TABLE 70. REST OF ASIA-PACIFIC CHEMOTHERAPY INDUCED ANEMIA MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 71. REST OF ASIA-PACIFIC CHEMOTHERAPY INDUCED ANEMIA MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 72. LAMEA CHEMOTHERAPY INDUCED ANEMIA MARKET, BY GRADE, 2022-2032 ($MILLION)
  • TABLE 73. LAMEA CHEMOTHERAPY INDUCED ANEMIA MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 74. LAMEA CHEMOTHERAPY INDUCED ANEMIA MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 75. LAMEA CHEMOTHERAPY INDUCED ANEMIA MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 76. BRAZIL CHEMOTHERAPY INDUCED ANEMIA MARKET, BY GRADE, 2022-2032 ($MILLION)
  • TABLE 77. BRAZIL CHEMOTHERAPY INDUCED ANEMIA MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 78. BRAZIL CHEMOTHERAPY INDUCED ANEMIA MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 79. SAUDI ARABIA CHEMOTHERAPY INDUCED ANEMIA MARKET, BY GRADE, 2022-2032 ($MILLION)
  • TABLE 80. SAUDI ARABIA CHEMOTHERAPY INDUCED ANEMIA MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 81. SAUDI ARABIA CHEMOTHERAPY INDUCED ANEMIA MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 82. SOUTH AFRICA CHEMOTHERAPY INDUCED ANEMIA MARKET, BY GRADE, 2022-2032 ($MILLION)
  • TABLE 83. SOUTH AFRICA CHEMOTHERAPY INDUCED ANEMIA MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 84. SOUTH AFRICA CHEMOTHERAPY INDUCED ANEMIA MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 85. REST OF LAMEA CHEMOTHERAPY INDUCED ANEMIA MARKET, BY GRADE, 2022-2032 ($MILLION)
  • TABLE 86. REST OF LAMEA CHEMOTHERAPY INDUCED ANEMIA MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 87. REST OF LAMEA CHEMOTHERAPY INDUCED ANEMIA MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 88. PFIZER INC.: KEY EXECUTIVES
  • TABLE 89. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 90. PFIZER INC.: PRODUCT SEGMENTS
  • TABLE 91. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 92. DR. REDDY'S LABORATORIES LTD.: KEY EXECUTIVES
  • TABLE 93. DR. REDDY'S LABORATORIES LTD.: COMPANY SNAPSHOT
  • TABLE 94. DR. REDDY'S LABORATORIES LTD.: PRODUCT SEGMENTS
  • TABLE 95. DR. REDDY'S LABORATORIES LTD.: PRODUCT PORTFOLIO
  • TABLE 96. JOHNSON & JOHNSON: KEY EXECUTIVES
  • TABLE 97. JOHNSON & JOHNSON: COMPANY SNAPSHOT
  • TABLE 98. JOHNSON & JOHNSON: PRODUCT SEGMENTS
  • TABLE 99. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
  • TABLE 100. AMGEN INC.: KEY EXECUTIVES
  • TABLE 101. AMGEN INC.: COMPANY SNAPSHOT
  • TABLE 102. AMGEN INC.: PRODUCT SEGMENTS
  • TABLE 103. AMGEN INC.: PRODUCT PORTFOLIO
  • TABLE 104. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 105. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 106. NOVARTIS AG: PRODUCT SEGMENTS
  • TABLE 107. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 108. 3SBIO GROUP: KEY EXECUTIVES
  • TABLE 109. 3SBIO GROUP: COMPANY SNAPSHOT
  • TABLE 110. 3SBIO GROUP: PRODUCT SEGMENTS
  • TABLE 111. 3SBIO GROUP: PRODUCT PORTFOLIO
  • TABLE 112. FIBROGEN, INC.: KEY EXECUTIVES
  • TABLE 113. FIBROGEN, INC.: COMPANY SNAPSHOT
  • TABLE 114. FIBROGEN, INC.: PRODUCT SEGMENTS
  • TABLE 115. FIBROGEN, INC.: PRODUCT PORTFOLIO
  • TABLE 116. ASTELLAS PHARMA INC.: KEY EXECUTIVES
  • TABLE 117. ASTELLAS PHARMA INC.: COMPANY SNAPSHOT
  • TABLE 118. ASTELLAS PHARMA INC.: PRODUCT SEGMENTS
  • TABLE 119. ASTELLAS PHARMA INC.: PRODUCT PORTFOLIO
  • TABLE 120. BRISTOL-MYERS SQUIBB COMPANY: KEY EXECUTIVES
  • TABLE 121. BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
  • TABLE 122. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT SEGMENTS
  • TABLE 123. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
  • TABLE 124. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
  • TABLE 125. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
  • TABLE 126. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
  • TABLE 127. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. CHEMOTHERAPY INDUCED ANEMIA MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF CHEMOTHERAPY INDUCED ANEMIA MARKET, 2022-2032
  • FIGURE 03. TOP INVESTMENT POCKETS IN CHEMOTHERAPY INDUCED ANEMIA MARKET (2023-2032)
  • FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 06. MODERATE THREAT OF SUBSTITUTES
  • FIGURE 07. LOW THREAT OF NEW ENTRANTS
  • FIGURE 08. MODERATE INTENSITY OF RIVALRY
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALCHEMOTHERAPY INDUCED ANEMIA MARKET
  • FIGURE 10. CHEMOTHERAPY INDUCED ANEMIA MARKET, BY GRADE, 2022(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF CHEMOTHERAPY INDUCED ANEMIA MARKET FOR GRADE 1, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF CHEMOTHERAPY INDUCED ANEMIA MARKET FOR GRADE 2, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF CHEMOTHERAPY INDUCED ANEMIA MARKET FOR GRADE 3 AND 4, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. CHEMOTHERAPY INDUCED ANEMIA MARKET, BY TREATMENT, 2022(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF CHEMOTHERAPY INDUCED ANEMIA MARKET FOR BLOOD TRANSFUSION, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF CHEMOTHERAPY INDUCED ANEMIA MARKET FOR ERYTHROPOIESIS STIMULATING AGENTS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF CHEMOTHERAPY INDUCED ANEMIA MARKET FOR IRON AND OTHERS SUPPLEMENTATION, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 18. CHEMOTHERAPY INDUCED ANEMIA MARKET, BY END USER, 2022(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF CHEMOTHERAPY INDUCED ANEMIA MARKET FOR HOSPITALS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF CHEMOTHERAPY INDUCED ANEMIA MARKET FOR CANCER CENTER, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF CHEMOTHERAPY INDUCED ANEMIA MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 22. CHEMOTHERAPY INDUCED ANEMIA MARKET BY REGION, 2022
  • FIGURE 23. U.S. CHEMOTHERAPY INDUCED ANEMIA MARKET, 2022-2032 ($MILLION)
  • FIGURE 24. CANADA CHEMOTHERAPY INDUCED ANEMIA MARKET, 2022-2032 ($MILLION)
  • FIGURE 25. MEXICO CHEMOTHERAPY INDUCED ANEMIA MARKET, 2022-2032 ($MILLION)
  • FIGURE 26. GERMANY CHEMOTHERAPY INDUCED ANEMIA MARKET, 2022-2032 ($MILLION)
  • FIGURE 27. FRANCE CHEMOTHERAPY INDUCED ANEMIA MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. UK CHEMOTHERAPY INDUCED ANEMIA MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. ITALY CHEMOTHERAPY INDUCED ANEMIA MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. SPAIN CHEMOTHERAPY INDUCED ANEMIA MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. REST OF EUROPE CHEMOTHERAPY INDUCED ANEMIA MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. JAPAN CHEMOTHERAPY INDUCED ANEMIA MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. CHINA CHEMOTHERAPY INDUCED ANEMIA MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. AUSTRALIA CHEMOTHERAPY INDUCED ANEMIA MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. INDIA CHEMOTHERAPY INDUCED ANEMIA MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. SOUTH KOREA CHEMOTHERAPY INDUCED ANEMIA MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. REST OF ASIA-PACIFIC CHEMOTHERAPY INDUCED ANEMIA MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. BRAZIL CHEMOTHERAPY INDUCED ANEMIA MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. SAUDI ARABIA CHEMOTHERAPY INDUCED ANEMIA MARKET, 2022-2032 ($MILLION)
  • FIGURE 40. SOUTH AFRICA CHEMOTHERAPY INDUCED ANEMIA MARKET, 2022-2032 ($MILLION)
  • FIGURE 41. REST OF LAMEA CHEMOTHERAPY INDUCED ANEMIA MARKET, 2022-2032 ($MILLION)
  • FIGURE 42. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 43. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 44. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 45. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 46. COMPETITIVE DASHBOARD
  • FIGURE 47. COMPETITIVE HEATMAP: CHEMOTHERAPY INDUCED ANEMIA MARKET
  • FIGURE 48. TOP PLAYER POSITIONING, 2022
  • FIGURE 49. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 50. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 51. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 52. DR. REDDY'S LABORATORIES LTD.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 53. DR. REDDY'S LABORATORIES LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 54. DR. REDDY'S LABORATORIES LTD.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 55. JOHNSON & JOHNSON: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 56. JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 57. JOHNSON & JOHNSON: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 58. AMGEN INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 59. AMGEN INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 60. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 61. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 62. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 63. 3SBIO GROUP: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 64. 3SBIO GROUP: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 65. FIBROGEN, INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 66. ASTELLAS PHARMA INC.: SALES REVENUE, 2020-2022 ($MILLION)
  • FIGURE 67. ASTELLAS PHARMA INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 68. BRISTOL-MYERS SQUIBB COMPANY: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 69. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 70. F. HOFFMANN-LA ROCHE LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 71. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 72. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY REGION, 2022 (%)